About US
Contact us
-
Bristol-Myers Squibb's Opdivo approved to treat blood cancer in EUBristol-Myers Squibb's drug Opdivo (nivolumab) has been approved for use in the European Union (EU) to treat classical Hodgkin lymphoma (cHL), a type of blood cancer. Hodgkin lymphoma is a cancer tha2016/12/20
-
New Myeloma Genome Project established to advance diagnosis and treatmentsCelgene, the Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences have collaboratively launched a new initiative known as the Myeloma Genome Project. The project is aimed2016/12/19
-
EIB to support Amryt Pharma’s new treatment for skin disordersThe European Investment Bank (EIB) will grant a €20m loan to support a new treatment being developed by Irish company Amryt Pharma for skin disorders. Epidermolysis Bullosa (EB) is a rare and inherit2016/12/19
-
UK scientists create map of licensed drugs to search for future treatmentsUK-based scientists at the Institute of Cancer Research (ICR) have created a map of all 1,578 licensed drugs and their mechanisms of action to identify ‘uncharted waters’ in the search for future trea2016/12/16
-
Cancer Research UK to invest £226m in cancer researchCancer Research UK has announced an investment of £190m in 13 centres over the next five years. Additionally, £36m will be invested by Cancer Research and the Departments of Health over f2016/12/16
-
NICE recommends GSK's new injectable asthma drug NucalaUK’s National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline's (GSK) new injectable asthma drug Nucala (Mepolizumab) for use in the country’s state-run health service2016/12/15
-
New research says UK stroke patients can benefit from new treatmentNew research has found that almost 10,000 UK stroke patients admitted to hospital each year could benefit from a new treatment. Researchers from Newcastle University, Northumbria University, Oxford A2016/12/15
-
Rwanda becomes third country to launch Novartis Access programmeNovartis has announced that Rwanda signed a memorandum of understanding (MoU) and became the third country after Kenya and Ethiopia to launch the Novartis Access programme. With this agreement, the R2016/12/14
-
Sweden’s Pharmalink obtains OMP designation for NefeconThe European Commission (EC) has granted orphan medicinal product (OMP) designation in the European Union (EU) to Swedish-based Pharmalink’s Nefecon (budesonide). Nefecon will be given for patients w2016/12/14
-
Bristol-Myers to pay $19.5 million in Abilify off-label marketing settlementAlmost a decade after settling up Abilify marketing allegations with the U.S. Justice Department, Bristol-Myers Squibb agreed to pay $19.5 million to settle similar claims at the state level. Announc2016/12/13